10-K: Assertio Holdings Reports 2024 Results; ROLVEDON Sales Reach $60.1 Million
Annual Results
Assertio Holdings, Inc. reports a net product sales of $120.8 million for 2024, driven by ROLVEDON, while navigating generic competition and strategic shifts.
Summary
- Assertio Holdings, Inc. generated $120.8 million in net product sales in 2024, compared to $149.5 million in 2023.
- ROLVEDON contributed $60.1 million to net product sales in 2024.
- INDOCIN net product sales were $26.8 million, impacted by generic competition.
- Sympazan generated $10.5 million in net product sales during 2024.
- The company's net loss from operations in 2024 was $24.5 million, a significant improvement from the $254.1 million loss in 2023.
- Comprehensive loss was $21.6 million in 2024, compared to $331.9 million in 2023.
- Operating cash flow was $26.4 million in 2024, down from $49.6 million in 2023.
- Cash, cash equivalents, and short-term investments exceeded $100 million as of December 31, 2024.
- The company is focused on oncology, neurology, and pain management.
- Assertio is actively looking to expand its product portfolio through acquisitions and licensing.
Sentiment
Score: 6
Explanation: The document presents a mixed sentiment. While there's improvement in net loss and a strong cash position, declining sales and competitive pressures temper the outlook.
Positives
- ROLVEDON has become the lead product, contributing significantly to revenue.
- Net loss from operations has substantially decreased year-over-year.
- The company maintains a strong cash position.
- Assertio is actively seeking to expand its product portfolio.
Negatives
- Overall net product sales decreased compared to the previous year.
- INDOCIN sales have been significantly impacted by generic competition.
- The company experienced inventory write-downs due to quality issues.
Risks
- The company faces intense competition from generics and other pharmaceutical companies.
- Failure to maintain attractive reimbursement for ROLVEDON could adversely affect sales.
- The company depends on single-source suppliers for APIs and manufacturing.
- Legal proceedings, including opioid-related lawsuits, could result in significant liabilities.
- Macroeconomic conditions and changes in regulations could impact the business.
Future Outlook
The company expects INDOCIN net product sales to continue to be impacted unfavorably by increasing competition in 2025. The company expects its cash, cash equivalents and short-term investments will be sufficient to fund its operations and make the required payments under its debt agreements due for the next 12 months.
Management Comments
- The company is focused on supporting patients by marketing products in oncology, neurology, and pain management.
- The company is actively looking to expand its product portfolio by acquiring additional products.
Industry Context
The pharmaceutical industry is highly competitive, with increasing pressure on pricing and reimbursement. The company faces competition from generic drug companies, compounding pharmacies, and other pharmaceutical companies.
Comparison to Industry Standards
- The document does not provide specific comparisons to industry standards or comparable companies.
- The document does not provide specific details about project benchmarks or results compared to industry peers.
Legal Proceedings
- The company is involved in multiple lawsuits, including opioid-related litigation, antitrust litigation, and shareholder litigation.
- A settlement in principle was reached in the qui tam litigation.
Stakeholder Impact
- Shareholders may be impacted by the volatility of the company's stock price and potential delisting from Nasdaq.
- Employees may be affected by restructuring plans and changes in management.
- Customers and patients may be impacted by changes in product availability and pricing.
Next Steps
- The company intends to vigorously defend itself in ongoing legal matters.
- The company is actively monitoring the closing bid price of its common stock and may consider available options to regain compliance with the Bid Price Rule.
Key Dates
| Date | Description |
|---|---|
| December 15, 2021 | Date of Asset Purchase Agreement by and among Otter Pharmaceuticals, LLC, Antares Pharma, Inc. and the Company |
| August 25, 2022 | Date of Indenture between the Company and U.S. Bank Trust Company, National Association, as trustee |
| February 13, 2023 | Date of Insider Trading Policy |
| February 23, 2023 | Date of Form of Convertible Notes Exchange Agreement |
| April 24, 2023 | Date of Agreement and Plan of Merger among the Company, Spade Merger Sub 1, Inc. and Spectrum Pharmaceuticals, Inc. |
| July 31, 2023 | Effective date of the acquisition of Spectrum Pharmaceuticals, Inc. |
| May 29, 2024 | Date of Amended and Restated Bylaws of Assertio Holdings, Inc. |
| May 29, 2024 | Date of Management Continuity Agreement between the Company and Brendan O'Grady |
| August 7, 2024 | Date of Non-Employee Director Compensation and Grant Policy |
| November 8, 2024 | Date of Enyart v. Assertio Holdings, Inc., et. al., In the Circuit Court of the Nineteenth Judicial Circuit, Lake County, Illinois, Case No. 2024LA00000842 |
| March 12, 2025 | Date of filing of the Annual Report on Form 10-K |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.